|

Lymphodepleting Conditioning Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • Daishi Tian1

Indications

  • Autoimmune Encephalitis (AE)1
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)1
  • Myasthenia Gravis (MG)1
  • Relapsing or Refractory Multiple Sclerosis (MS)1
  • Multiple Sclerosis1

Other1 trial

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.